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Abstract: Coronavirus disease 19, or COVID-19, is an infection associated with an unprecedented
worldwide pandemic caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-
CoV-2), which has led to more than 215 million infected people and more than 4.5 million deaths
worldwide. SARS-CoV-2 cell infection is initiated by a densely glycosylated spike (S) protein, a
fusion protein, binding human angiotensin converting enzyme 2 (hACE2), that acts as the functional
receptor through the receptor binding domain (RBD). In this article, the interaction of hACE2 with the
RBD and how fusion is initiated after recognition are explored, as well as how mutations influence
infectivity and immune response. Thus, we focused on all structures available in the Protein Data
Bank for the interaction between SARS-CoV-2 S protein and hACE2. Specifically, the Delta variant
carries particular mutations associated with increased viral fitness through decreased antibody
binding, increased RBD affinity and altered protein dynamics. Combining both existing mutations
and mutagenesis studies, new potential SARS-CoV-2 variants, harboring advantageous S protein
mutations, may be predicted. These include mutations S13I and W152C, decreasing antibody binding,
N460K, increasing RDB affinity, or Q498R, positively affecting both properties.
Keywords: SARS-CoV-2; Spike protein; hACE2; protein structures
1. Introduction
Coronavirus disease 19, or COVID-19, is an infection associated with an unprece-
dented global pandemic caused by the severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2), which resulted in more than 215 million infected people and more than 4.5
million deaths [1–3]. SARS-CoV-2 was first identified in December 2019 in Wuhan, Hubei
province of China, in individuals exposed at a seafood/wet market and was successfully
isolated and sequenced in January 2020 [1]. Genetic evidence suggests that the virus origi-
nates from animals, particularly bats, as SARS-CoV-2 has 96% sequence identity to a strain
found in bats (BatCov RaTG13), possibly having pangolins, minks, turtles, or snakes as the
intermediate host [1,4].
Coronaviruses (CoVs) are a group of RNA viruses belonging to the subfamily Ortho-
coronaviridae that cause disease in a variety of domestic and wild animals (e.g. porcine,
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bovine, feline and avian, and bat and whale strains) [5]. A defining characteristic in all
CoVs is the crown-like viral particle, from which their name is derived [6,7]. It consists of
three major structural proteins (spike, membrane, and envelope), that protrude from the
viral envelope and have a critical function in cell recognition and fusion [6]. Additionally,
the nucleocapsid (protein N) binds and stabilizes the viral genome (Figure 1) [8].
Figure 1. Representation of SARS-CoV-2 main structural proteins.
Furthermore, they have the second largest RNA viral genome, a positive sense genome
of single-stranded RNA (+ssRNA), with an average size of 30 kb [9]. Importantly, CoVs
have a large genome with a high mutation rate (one nucleotide per 1000 to 10,000 nu-
cleotides replicated), associated with the RNA dependent RNA polymerase, and a random
template switching during RNA duplications, that causes a high frequency of homologous
RNA recombination [5]. These characteristics are responsible for the special plasticity of
CoVs when it comes to accommodating and modifying genes, explaining the broad range
of hosts infected by them [5].
Taken together, these factors have led to a diversity of strains and genotypes highly
adaptable to new hosts and ecological niches, causing major zoonotic outbreaks [5].
SARS-CoV-2 is transmitted via aerosols or droplets, typically within one metre or in
poorly ventilated and/or crowded indoor settings, and possibly by touching contaminated
and eyes, nose, or mouth, with both symptomatic and asymptomatic patients being the
main source of infection [1,10]. The immune response appears to be characteristic of
each individual, with a unique collection of antibodies (Abs) and varying efficacy of viral
neutralization potency observed [11].
Over time, numerous SARS-CoV-2 variants have been reported, differing by one or
more mutations from the first virus sequenced, the so-called original virus variant, which
corresponds to the Wuhan strain [12]. Some of these have been classified as variants of
concern (VOC), defined by their features, such as increased transmissibility, virulence
and disease severity, decreased Ab neutralization or vaccine efficiency and/or errors in
current detection protocols [13–15]. The list of variants of concern is frequently updated
according to new information, by the Centers for Disease Control and Prevention (CDC),
World Health Organization or the European Centre for Disease Prevention and Control
(ECDC) [14–18]. Additionally, some variants are classified as variants of interest (VOI),
characterized by mutations with predicted negative features, although with insufficient
evidence, by limited prevalence or epidemiological data suggesting an emerging risk to
public health [14–16]. Variants can also be de-escalated, particularly if they cease to circulate,
if, despite circulating, they have a negligible effect on the epidemiological situation or if
scientific evidence shows no concerning features (Table 1) [14].
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50% increased
transmission Minimal impact Increased severity VOC | VOC | DE [14,16]




















treatment VOC | VOC | VOC [14,16]
Epsilon B.1.427/B.1.429 USASep-2020 Unclear Reduced neutralization No effect reported NA | NA | DE [14]
Zeta P.2 BrazilNov-2020 No effect reported
Potential reduced
neutralization1 No effect reported NA | NA | DE [14]









neutralization1 No effect reported NA | NA | DE [14]
Iota B.1.526 USADec-2020 No effect reported Reduced neutralization
Potential reduced












neutralization No effect reported NA | VOI | VOI [14,26]
Mu B.1.621 ColombiaJan-2021
Potential increased
transmissibility1 Reduced neutralization No effect reported NA | VOI | VOI [14]
Abbreviations: VOC—variants of concern. VOI—variants of interest. DE—deescalated. NA- not available. Note: 1 Potential effect is predicted from the mutations present and their effect in previous studies. Not
directly observed in the variant.
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Glycoprotein: Cell Recognition and Infection
As with all CoVs, SARS-CoV-2 cell infection is initiated by a densely glycosylated spike
(S) protein, a trimeric class I fusion protein that binds to human angiotensin converting
enzyme 2 (hACE2), acting as the functional receptor [1]. hACE2 expression is ubiquitous
in the human body and although the degree of expression varies between organs, it is
at its highest in type II alveolar epithelial cells in the lungs, which indicates the primary
target for the virus [27]. In addition, hACE2 expression is also high in other tissues, such as
myocardial cells, kidney and enterocytes, which explains less common symptoms as well
as the multiorgan injuries observed in severe cases [27].
In general, the S protein exists in two main conformations, prefusion and post-fusion,
requiring major structural rearrangements after recognition to promote cell fusion [28].
The S protein consists of two subunits (S1 and S2) responsible for cell recognition and mem-
brane fusion, respectively [1]. Although S1 and S2 are originally covalently bound, there is
a cleavage site between the subunits, where host serine proteases, such as furin, transmem-
brane protease serine protease 2 (TMPRSS2) or cathepsin L, cleave the protein [1,11,28].
Notably, TMPRSS2 is co-expressed with hACE2 in nasal epithelial cells, lungs and bronchial
branches [11]. When the S1 and S2 subunits are cleaved, the protein is activated and can
undergo the necessary conformational changes to achieve the post-fusion conformation
and consequently enable cell infection (Figure 2) [1,28].
Figure 2. (A) Single chain in trimeric spike protein with subunit S1 (Tan) and S2 (Cyan) in 7A94. (B) Post-fusion conformation
of all S2 units in the trimeric spike in 6LXT. (C) S1 subunit, with the RBD highlighted in 7A94 [29].
The S1 subunit formed of the N-terminal domain (NTD) and a receptor binding
domain (RBD) that directly interacts with hACE2. Therefore, it is considered a key target
for antivirals and neutralizing Abs, accounting for 90% of the neutralizing activity in
convalescent sera [1,30–32]. Despite the low percentage of NTD-directed Abs, some are
still potent inhibitors [32]. The NTD and two neighbouring regions, namely a β-hairpin
(residues 140-158) and a loop (residues 245-264), are collectively termed an antigenic
supersite, where NTD directed Abs bind [32]. The NTD-directed Abs neutralizing activity
is due to both viral entry blocking and also limiting cell-to-cell spread of the virus [32].
Regarding the RBD, it can be further divided in two structural domains, a highly
conserved core, and a variable external subdomain that binds hACE2 [1].
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Subunit S2 contains two heptad repeats, a transmembrane domain, a cytoplasmic
tail, a central helix, and the fusion peptide that is critical for the main function of S2 of
merging the host and viral cell membranes (Figure 2) [31]. Additionally, N-linked glycans
are extensively present along the molecule and are essential in proper folding [1,31].
Even if the S protein is activated through the cleavage process, the RBDs can still
be inaccessible for interaction [28]. Each RBD can be either down (closed conformation),
inaccessible for interaction, or up (open conformation). The open conformation is the
necessary state for recognition, with the recognition motifs protruding from the S protein
(Figure 3) [1,28].
Figure 3. Spike protein conformations, with each spike monomer is represented by a colour (blue, red, gray). (A) All RBD
down (PBD 6VVX) (B) 1 RBD up (PDB 7A94) (C) 2 RBD up (PDB 7A97) (D) All RBD up (PDB 7A98) [33].
To engage the host cell receptor, the RBD undergoes hinge-like conformational changes,
transiently switching from a down conformation, to a less stable up conformation. Each
RBD is capable of individually changing its conformation (Figure 3) [28]. When ACE2
interacts with the RBD, it binds tightly and stabilizes the up conformation [1,34].
In this review, the interaction of hACE2 with the RBD is explored, namely the im-
portant contacts between proteins and how this interaction can be modulated to increase
affinity or reduce Ab binding. Additionally, we will also try to elucidate how the binding
of hACE2 affects S1/S2 interaction, the importance of this interaction in cell fusion and
how mutations can influence infectivity and immune response. This information may be
important to predict or explain the changes in infectivity or immune response for new
variants, which has been studied for the SARS-CoV-2 Delta variant, currently becoming
the most prevalent variant worldwide [35].
A total of 37 structures were selected, three of which are complexes that, despite
involving the SARS-CoV-2 S protein, also have an Ab or non-human ACE2, and therefore
would not reliably represent the critical interactions between the virus and the human
protein. The remaining structures can be broadly divided into two categories: studying
the RBD-hACE2 interaction or full spike protein behaviour, focusing on the conformation
changes from recognition to fusion (Figure 4) [21]. Furthermore, some structures also have
hACE2 in a complex with broad neutral amino acid transporter 1 (B0AT1), which stabilizes
hACE2 homodimers [36].
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Figure 4. Organizational scheme of all structures found in this review. Molecular graphics analyses were performed with
UCSF Chimera and Visual molecular dynamics [29,33]. A homology model for the S protein of SARS-CoV-2 Delta variant
was created using SWISS-MODEL [37].
2. Discussion
2.1. SARS-CoV-2 Spike RBD – hACE2 Interaction
2.1.1. Structures with No Mutation
The RBD/hACE2 interaction structures represent the domains of both proteins that
contribute to this interaction, providing the basis for computational protein-protein in-
teraction studies, mutation analysis, drug design and computational models of the full
spike protein, as it is harder to maintain a similar resolution for significantly larger struc-
tures [38–41].
The structures used for these analyses represent the wild-type SARS-CoV-2 S pro-
tein/ACE2 interaction without mutations (PDB 6VW1/6M0J/6LZG), with an Root Mean
Square Distance (RMSD) of 0.32 Å between them (Figure 5) [39,42].
Figure 5. Alignment and superposition of the models representing the interaction with no mutations
(PDB 6VW1/6M0J/6LZG) [33].
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Consistently, in all structures focusing on this interaction in wild-type SARS-CoV-2
S protein, the contact interface is divided into two clusters at both ends of the α1 helix in
hACE2, leaving a central cavity filled with water [40,43]. In these sections, there are over
10 H-bonds, multiple salt bridges, π-stacking and non-polar interactions [36,40,43].
In the N-terminal portion of the α1 helix, a network of H-bonds is present between
Gln493, Gly496, Gln498, Thr500 and Asn501 from the RBD and Lys31, His34, Glu35, Tyr41,
Gln42, Leu45, Lys353, and Arg357 from hACE2 (Figure 6B) [43]. Additionally, in the
C-terminal portion there are H-bonds (Gln474-Gln24, Asn487-Tyr83), Van der Waals forces
(Phe486- Met82) and π-stacking interactions (Tyr489-Phe28, Phe486-Tyr83), with more
interactions through the middle cavity (Lys417/Tyr453 from RBD and Asp30/His34 from
hACE2) (Figure 6C) [36,44].
Figure 6. Interface between SARS-CoV-2 S protein RBD (cyan) and hACE2 (tan), in the S protein/ACE2 interaction without
mutations structure (PDB 6M0J). (A) Full view of RBD—hACE2 interface (B) N-terminal portion of the α1 helix with a
network of H-bonds (C) C-terminal interactions, with π-stacking interactions, h-bonds and Van der Waals forces [29].
Some structures also focus the RBD without mutations (PDB 7KMB/7A91/7A92),
nevertheless they are reported in studies describing the behaviour of the entire spike
protein, where the interaction region was built from non-mutated RBD focused structures
(PDB 6VW1/6M0J/6LZG) [39,45].
Determining the structure of full-length human ACE2 bound to the RBD (PDB 6M17)
requires the use of an amino acid transporter (B0AT1) to stabilize the protein. When
bound to B0AT1, each hACE2 can bind an RBD, suggesting that native dimeric hACE2 can
accommodate two S protein trimers [36] Moreover, B0AT1 is not involved in dimerization,
thus hACE2 may be a homodimer even in the absence of B0AT1 [36]. Critically, the distance
between the ACE2 molecules, particularly for residue D615, is only 53 Å, and thus it
appears unlikely that the dimeric ACE2 can engage more than one RBD from the same
spike protein without substantial conformational changes, although it could bind two RBDs
from separate viral particles [46].
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2.1.2. Structures with Mutations
The main goal of determining the structure of a focused RBD without mutations is to
understand the behaviour of the wild-type strain and to describe the main interactions of
the S protein with hACE2 [43]. When introducing mutations or studying different strains,
the goal may be to obtain new therapeutic agents based on either hACE2 or S protein, and
to understand why new strains behave differently [23,24,41,47].
The four structures that focus the RBD and have mutations can be further catego-
rized according to the aim of finding new anti-SARS-CoV-2 therapeutic agents (PDB
7DMU/7BH9), or to study mutations in new strains (PDB 7NXC/7LO4).
An hACE2 with mutations to increase the affinity to the viral protein was developed as
an anti-SARS-CoV-2 therapeutic agent (PDB 7DMU), achieving more than 100-fold increase
in blocking activity, when compared to the wild-type hACE2 [41].
The interaction pattern of engineered hACE2 with the RBD is similar to wild-type
hACE2, extending a hydrophobic pocket and adding a new H-bond (K35 - Q493, from
hACE2 and RBD, respectively), shortening the distance between hACE2 α1-helix to the RBD
by ~1Å [41]. The use of recombinant hACE2 instead of Abs has an important advantage,
given that the resulting mutants with escape mutations have decreased binding affinity to
both the engineered and wild-type hACE2, leading to a decrease in virulence [41].
On the other hand, developing a competitive inhibitor from the RBD also holds
potential for significant inhibition, particularly as the affinity of the inhibitor with the
hACE2 is increased. The RBD inhibitor with the highest binding affinity found (PDB 7BH9)
has a RSMD of 0.66 Å when superimposed with the wild type [38]. It was developed from
multiple libraries of SARS-CoV-2 clones generated by random mutagenesis and selection
of best expressing clones, with several cycles of mutation and testing, attempting to mimic
natural evolution in vitro [38].
The mutated RBD (PDB 7BH9) presents, among others, eight amino acid changes
actively engaged in the interaction with hACE2, namely V445K, N460K, I468T, T470M,
S477N, E484K, Q498R and N501Y. These changes result in additional H-bonds, salt bridges
and increased networks of interactions, both stabilizing the structure and resulting in
a more positive surface, complementary to the negatively charged hACE2 interaction
interface (Figure 7) [38]. The engineered protein can block viral entry and replication, due
to an optimized binding, while maintaining no negative effect in the hACE2 enzymatic
physiologic activity [38].
Although the optimized structure shows a possible path to design inhibitors, it is
noteworthy which mutations are appearing and the sequence in which they appear. Some
of the mutations present in the optimized RBD are also present in new variants as critical
mutations in variants of concern, appearing often and early in the mutagenesis process,
particularly mutations N501Y (variants Alpha, Beta and Gamma) and E484K (variants Beta
and Gamma) [48–50]. This may suggest that the in vitro process is possibly mimicking
natural evolution, and that artificial selection may have important predictive capabilities
over new emerging mutations [41,48,49].Considering the main variants in circulation, only
one mutation providing a clear survival advantage is located outside the RBD (mutation
D614G, discussed in more detail ahead) [38,51]. The most common mutations appearing
in the later phases, suggest that the next variants with increased infectivity might include
mutation Q498R or N460K, as they both significantly increase the affinity and emerged late
in the optimization process [38].
Besides predicting potential mutations, the optimized structure may also predict the
effect on immune evasion. Analysis of 96 Abs revealed that 28 of them bind outside of the
hACE2-binding domain, and the interaction was impaired in 9 Abs with major clashes.
Additionally, mutation Q498R, besides increasing the affinity with hACE2, was frequently
involved in clashes with Abs [38].
Regarding natural occurring mutations, two structures are available, a strain with
mutation G485R and variant Gamma.
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Figure 7. Superimposition and alignment of wild-type RBD and hACE2 (PDB 6LZG) (light blue) and
mutated RBD (PDB 7BH9) (hACE2—dark blue ribbon/SARS-CoV-2 S protein—grey ribbon). The
closer distance between the chains from the initial to the optimized model reflects the additional
interactions established [33].
In the structure with mutation G485R (PDB 7LO4), residue 485, mutating from glycine
to arginine, is not directly involved in the hACE2-SARS-CoV-2 S protein interaction, but
close to Ab binding epitopes and in a loop region that makes multiple contacts with hACE2.
This mutation leads to a rotation in the loop, affecting some interacting residues without
significantly reducing the affinity [47]. Nevertheless, the conformational changes in the
loop correlate with previous evidence that this mutation plays a role in antigenic escape
from neutralising Abs, disrupting interactions involving E484 and F486 (Figure 8) [47].
Figure 8. Structural superimposition between the wild-type RBD (Tan) (PDB 6M0J) and with the
G485R RBD mutation (Cyan) (PDB 7LO4), with conformational change in the highlighted loop. The
RMSD between structures is 0.42Å [29].
Variant Gamma (PDB 7NXC), has been a cause for concern since it emerged in Brazil in
the final months of 2020, showing increased transmissibility and low cross immunity [23,50].
One of the defining characteristics of this variant is the high number of mutations, par-
ticularly in the spike protein, with three mutations specific to the RBD (K417T, E484K
and N501Y), that lead to a 19-fold increase in affinity compared to the Wuhan strain [50].
Mutation K417T deletes a salt bridge with D30 from hACE2, potentially leading to a
decreased affinity. Critically, it hinders Ab binding, contributing to the immune escape
observed with this strain [24,52]. The increased affinity is due to both mutation E484K,
improving the electrostatic complementarity with the negatively charged hACE2, through
the change from a carboxylic acid (E) to an amine group (K), and mutation N501Y creating
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an additional ring stacking interaction, with the change from the short-chained asparagine
to the aromatic chained tyrosine (Figure 9) [24].
Figure 9. Asparagine-501 from wild-type RBD (PDB 6M0J, carbon atoms in blue) and tyrosine-501
from Gamma variant (PDB 7NXC, carbon atoms in yellow), capable of establishing an additional
pi-stacking interaction with tyrosine-41 from hACE2 (bottom) [29].
2.1.3. RBD Only Structures—Final Remarks
The interaction interface and critical contacts between hACE2 and SARS-CoV-2 S pro-
tein are well understood. Besides having quality structures available, mutations to the RBD
critical amino acids result in predictable and replicable changes in binding affinity [38,40].
When considering the differences between the wild-type RBD (PDB 6VW1/6M0J/6LZG)
and the optimized RBD (PDB 7BH9), there is a path for increased binding, infectivity,
and potential new variants. Some changes in the optimized RBD required two nucleotide
mutations, which takes longer in natural selection [38]. Importantly, N501Y and E484K
were present, emerged frequently in earlier stages and have already been found in emerg-
ing variants, suggesting some predicting potential for possible new variants [24,38]. The
selection of new strains may also be related to the use of low-quality masks, as strains with
a higher viral load or a tighter binding spike protein have an advantage over wild-type
SARS-CoV-2 [36,38,39,44].
2.2. SARS-CoV-2 Full Spike Protein—hACE2 Interaction
2.2.1. Mutations in the Spike Protein
In various structures of the full spike protein, some mutations appear often, namely
mutation of amino acids 986 and 987 to proline and mutations in the S1/S2 cleavage
site. The introduction of two consecutive proline residues, at the beginning of the central
helix (residues 986 and 987), is a general strategy to retain β-coronavirus S proteins in the
prototypical prefusion conformation, which facilitates the study of this conformational
state [53]. The same occurs with the cleavage site (RRAR) mutation, as mutating this
sequence stabilizes the prefusion structure, since cleavage activates the protein [1,28]. This
cleavage site, recognized by host proteases, is fundamental for the virus, allowing the
conformational changes leading to the post-fusion structure [54]. In vivo, it increases
infectivity, as proteases is ubiquitously present, and importantly, this effect is present
not only in SARS-CoV-2 but also in Influenza viruses and human immunodeficiency
viruses [55]. Furthermore, this is a distinct characteristic of SARS-CoV-2 and absent in
other β-coronaviruses, particularly SARS-CoV [55].
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2.2.2. SARS-CoV-2 Full Spike Protein—hACE2
The RBD-hACE2 focused structures highlight the main interactions leading to receptor
recognition by SARS-CoV-2, and they are critical for spike protein function. Nevertheless,
the spike protein has additional functions in budding and cell fusion, mainly through
conformational changes caused by the interactions with hACE2 [1,28,56]. Structure de-
termination for the full spike protein will necessarily have limitations due to its size, and
usually other structures are used to build the RBD portion of the structure [39]. However,
they give an important insight into the major conformational changes to the entire protein
and into critical steps culminating in cell fusion and infection [39,56].
The process through which membrane fusion occurs, particularly the entry cell process,
is still undefined. This seems to include the interaction between hACE2 and the spike
protein, and after recognition, entry occurs via the endosomal pathway or direct cell surface
interaction [45]. In both pathways, protein activation requires a protein, either cathepsin L
or TMPRSS2 respectively, as full inhibition of both blocks viral entry [45]. When considering
the endosomal pathway, it is important to notice the change in pH and the resulting effects
in protein structure, particularly in amino acids containing multiple ionizable groups [45].
The main difference between the structures found at physiological pH (PDB 7KNE/
7KNB/7KMS) and at pH 5.5(PDB7KNI/7KNH/7KNE) is the distribution of up and down
RBDs. At acidic pH, no double or triple up conformations are observed, with small
changes observed at pH 4.5 and pH 4.0. Starting at pH 5.5, a region in subunit S2 near the
fusion peptide, rich in aspartic acid residues, undergoes a pH-dependent switch, twisting
the orientation of disulphide bonds in the structure and causing RBD movement. The
domain switch, caused by the pH in endosomal entry, represents an all-RBD-down locking
strategy of immune evasion, that SARS-CoV-2, as other CoVs, potentially uses to avoid
neutralization by RBD-up-recognizing Abs [45].
2.2.3. Before and after hACE2 Binding
The S protein gradually undergoes conformational changes as hACE2 binds to the
each RBD. Particularly in the first hACE2 binding event, a major conformational change
is observed, with a rigid body rotation and center of mass of the S protein movement,
exposing the remaining unbound RBDs, further stabilized due to the high affinity with
hACE2 [45]. The steps leading from a closed and unbound S protein to a full hACE2
binding decrease the contact area between each S1 and the corresponding S2, resulting in a
weaker interaction, with the conformational changes driven by hACE2 binding events [39].
These rearrangements and restructuring events in subunits S1 and S2 may have important
implications in fusion activation, as the fusion peptide is preceding the S1/S2 contact
area [39]. Critically, the cleavage event increases the percentage of RBDs in the up confor-
mation from the closed trimer (PBD 7DX5) to the open timer (PBD 7DX9), increasing the
ability to bind the first hACE2 [56].
Briefly, upon cleavage between S1 and S2 domains, an increase in spike trimers in
open conformation is observed (unbound open trimer—PBD 7A93), followed by hACE2
binding (1 RBD bound, 2 RBD down—PBD 7A94) and a major conformational change,
exposing further RBDs (1 RBD bound, 2 RBDs up - PBD 7A95/7A96) and hACE2 binding
(3 RBD bound—PBD 7A97/7A98). The major conformational change and further binding
weakens the S1−S2 interaction preceding the fusion peptide region, priming the S trimer
for helical rearrangements in S2, required for viral−host cell membrane fusion [39].
The SARS-CoV-2 original viral S protein population consists mainly of RBD down
structures, with S1/S2 uncleaved. The resulting tightly closed conformation of the spike
protein is indicative of a conformation masking mechanism for immune evasion of SARS-
CoV-2, similar to the changes found with low pH, potentially neutralizing RBD-binding
Abs [39]. This feature is also described for other CoVs, such as SARS-CoV and MERS-
CoV [42]. The ratio of spike proteins with up or down conformation before and after
the first hACE2 binding event has a larger increase in SARS-CoV-2, indicating that the
conformational masking may be more efficient [42].
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Another important feature of CoVs, particularly regarding immune evasion, is glyco-
sylation. The large number of N-linked glycans covering the surface of the spike protein of
SARS-CoV-2, SARS-CoV and MERS-CoV could pose a challenge to antigen recognition,
which thus may help the virus evade immune response [42]. However, in the residues close
to the S1/S2 cleavage site, the SARS-CoV-2 trimer forms a glycan hole, a region with less
glycosylation than the rest of the protein, resulting in an unhindered access by cleavage
enzymes [42].
Taking in account all the events occurring from recognition to cell fusion, SARS-CoV-2
is overall very sensitive to the presence of hACE2, with the open state trimer existing only
momentarily in the absence of hACE2 and frequently in its presence. This interaction shifts
the protein population characteristics, favouring receptor binding, protein activation and
the post-fusion state [42].
2.2.4. Spike Protein Mutation D614
From all the mutations in prevalent variants by June 2021 worldwide, mutation D614G
is the only one located outside the RBD, and therefore with no direct effect in affinity (PDB
7DF4), but nevertheless, causing increased infectivity and transmission [42,57]. In the
closed conformation, portions near the fusion peptide, such as the subdomain 2 and heptad
repeat 1, form multiple hydrogen bonds and salt bridges. From the six bonds established
in this zone, four have a direct contribution from the side chain of residue D614, suggesting
that this amino acid may be essential for this interaction and subsequent stabilization of
the prefusion conformation [42,57].
In general, mutation D614G greatly disturbs the interactions between subunits S1 and
S2, due to the weakened interactions established by the side chain of glycine, in comparison
with aspartic acid [42,57]. As a result, the energy barrier for the conformational change
is reduced and SARS-CoV-2 D614G strains have increased sensitivity to the presence of
hACE2, which could be the underlying mechanism for enhanced infectivity observed in
these strains [42]. On the other hand, given the increase of RBDs in the up position, these
strains are more susceptible to neutralization by RBD-directed Abs [58].
2.2.5. Full Spike Protein Neutralization Strategies
Soluble hACE2 has demonstrated a protective role against SARS-CoV2 infection,
blocking viral entry in cell cultures and human organoids. Due to this activity, recombinant
soluble hACE2 is already enrolled in several clinical trials, as a promising treatment for
SARS-CoV-2 infection [59]. The use of ACE2 as a neutralizing agent can be achieved in
several ways, either by increasing the affinity or engineering dimers and trimers capable
of binding several RBDs. The spike protein can bind three hACE2 molecules and, as
such, it is expected that a trimeric ACE2 with a linker can inhibit SARS-CoV-2. S proteins
bound to one or more hACE2 have guided the design of ACE2-based viral inhibitors (PDB
7KJ2/7KJ3/7KJ4) [59]. The binding strength of constructs using a monomer, a dimer, and a
trimer of hACE2, with engineered linkers, increases as expected. The trimer structure was
then optimized, resulting in a trimeric ACE2 with a 200-fold increase in binding affinity,
when compared with soluble wild-type hACE2, all without hindering the physiological
functions of ACE2 in the angiotensin-renin system [59]. Notably, the neutralization potency
of ACE2 constructs gradually increases with the size of the construct, and correlates strictly
with the binding affinity, suggesting that the interaction between the RBD and hACE2 is
the main component of neutralization [59]. Further improvements of these ACE2-based
therapeutic candidates include modifications to enhance protein stability, to modulate
peptidase activity and to increase its in vivo residence time in circulation [59].
An engineered ACE2-rigid-foldon, as a trimeric protein (PDB 7CT5) inhibits eight
naturally occurring mutants, including D614G and seven other RBD domain mutants [46].
The inhibition of SARS-CoV-2 by the trimeric hACE2 occurs due to the simultaneous
binding of all three RBD in each spike trimer, which stabilizes the viral protein in a three-
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RBD-up conformation and, as this was the only conformation found, it shows the striking
ability of these trimers to change the conformation of the spike protein population [46].
2.2.6. Spike Vaccine Candidate
Considering Ab potency for virus neutralizing effects, competition with hACE2 for
RBD binding is a key predictor [30]. Hence, the spike protein is the prime candidate
for vaccine development, in order to elicit the appearance of Abs directed at the spike
protein. The S protein resulting from the coding sequence (mRNA) in the vaccine candidate
BNT162b2 (PDB 7L7F), consists of a trimeric S protein capable of binding hACE2 with
high affinity and structurally intact receptor binding sites. This is achieved due to a
stabilization of the protein in the prefusion conformation, by substitution of residues 986
and 987 [60]. The altered spike protein induces a high functional Ab response both in mice
and non-human primates (macaques), protecting them from infection with SARS-CoV-2,
demonstrated by an absence of detectable RNA by RT-qPCR in the lower pulmonary
tract [60].
2.3. Delta Variant
Spike protein mutations can be selected for either increased infectivity, generally from
an increased interaction with hACE2, or decreased immune response, affecting Ab binding.
As such, mutations in the spike protein are a fundamental aspect in variants of concern.
Notably, one mutation is common to all prevalent strains worldwide, D614G, associated
with increased infectivity, although with no direct effect to the RBD [42].
Variant Delta appeared in India in late 2020 and is becoming the dominant strain world-
wide, responsible for most infections in the US, Europe, South Africa and Australia [61,62].
Importantly, this variant combines mutations affecting infectivity and potential immune
escape (Table 2) [16]. Early data have shown that viral loads are 1,000 times higher with
this strain, when compared with the Wuhan strain, which also contributes to increased
transmission [63].
Table 2. List of mutations found in the spike protein of the Delta variant.
Mutation Location Effect on Affinity Effect on Immune Response Additional Information References
T19R S1/NTD No effect reported Affects NTD-directed Abs
Change in NTD
antigenic site [32,64]
E156- S1/NTD No effect reported Affects NTD-directed Abs
F157- S1/NTD No effect reported Affects NTD-directed Abs
R158G S1/NTD No effect reported Affects NTD-directed Abs
K417N RBD Potential decrease inaffinity
Moderately decreases
RBD-directed Abs
Affects only less important class
of Abs [24,52]
L452R RBD No effect reported Severely affectsRBD-directed Abs None [52,64]
T478K RBD Increases electrostaticcomplementarity
Moderately decreases
RBD-directed Abs Three additional H-bonds formed [65–67]





Increased viral loads and
transmission
[52,58]
P681R S2 No effect reported No effect reported Increased S1/S2 cleavage andviral fusion [66]
D950N S2 No effect reported No effect reported Change protein dynamics [67]
Abbreviations: NTD—N-terminal domain, RBD—receptor binding domain.
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Regarding infectivity, this strain possesses mutation D614G and one mutation in the
RBD, T478K. Despite no effect with direct bonds or contacts, it increases the electrostatic
complementary between the proteins [65]. As such, it is hypothesised that the Delta variant
emerged mainly as a result of reduced immune recognition and enhanced transmissibility
nonrelated with affinity (effects from mutations D614G, P681 and D950N) [68]. Importantly,
mutation N501Y is not found in the Delta variant, in contrast with all other variants of
concern.Mutation N501Y results in the highest increase in hACE2 affinity conferred by a
single RBD mutation [52].
Potentially fundamental for immune escape are mutations K417N, and particularly
L452R, both affecting Ab binding, and occurring in the RBD [64]. L452R has also appeared
in variant Epsilon identified in California, reaching a maximum of 20% of new cases in the
United States, before variant Delta became prevalent [61,69]. Although no structure on
the Delta variant RBD is available, a homology model of the Delta variant RBD was built,
using SWISS-MODEL, and the effect of specific and new mutations can be predicted [37].
Homology modelling is a method that predicts a 3D structure based on the aminoacidic
sequence, with the only requirement of an existing experimental structure with at least 30%
sequence identity [70]. The genome selected to represent the Delta strain was MZ377116,
retrieved from the SARS-CoV-2 Data Hub (NCBI Virus) [71].
Mutation L452R causes a steric hindrance to Ab binding, retrieved from structure
7CM4, without affecting binding to hACE2 (Figure 10) but causing a greater than 10-fold
decrease in neutralization potency for RBD-specific Abs [61,69]. Crucially, variant Epsilon
has additional mutations, S13I and W152C, resulting in severe decrease of neutralization for
NTD-directed Abs, due to a new disulphide bond inducing a conformational change [64].
In the Delta variant, mutations T19R, E156-, F157- and R158G severely affect NTD directed
Abs, due to the adoption of an alpha-helical conformation, instead of the original β-
strand [64,68].
Figure 10. Mutation L452R, with the original variant from wild-type RBD (PDB 6M0J) (cyan) and the homology model
of Delta variant (tan), obtained from genome MZ377116.1 (A) Superimposition of RBDs from original variant and Delta
variant. Steric hindrance observed with Arg107 from Ab from structure 7CM4, due to a longer side chain in Delta variant
(B) RBDs of original and delta variant structures with no steric hindrance regarding hACE2 [29].
Variant Epsilon has been deescalated from variant of concern due the decrease in
community transmission, being replaced by the Delta variant [14,16].
3. Conclusions
The structures available in the Protein Data Bank provide important insights into
SARS-CoV-2 spike protein behaviour, clarifying the conformational changes across the
protein leading to post-fusion conformation and cell infection. In general, the spike protein
is highly sensitive to the presence and binding of hACE2 to the RBDs, with an allosteric
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effect, destabilizing the S1/S2 interaction and facilitating the final conformational change.
The affinity of the complex formed in cell recognition is critical for infectivity, with conse-
quences in the epidemiology of SARS-CoV-2. As such, the RBD is also an important target
for neutralizing Abs.
The appearance of new variants has increased SARS-CoV-2 fitness, mainly by in-
creasing infectivity, or decreasing immune response. The Delta variant carries particular
mutations associated with increased viral fitness through decreased antibody binding, in-
creased RBD affinity and altered protein dynamics, which justifies the increased prevalence
worldwide [67,72]. Despite this, some of the most common mutations increasing affinity in
other variants are absent, which still show potential for evolution [52,61].
The ability to predict infectivity and immune escape for new variants is crucial to
decrease their impact. As such, mutagenesis studies have also shown an important pre-
dicting capacity for the major mutations in current variants of concern [38]. Combining
both existing mutations and mutagenesis studies, new potential SARS-CoV-2 variants,
harboring advantageous S protein mutations, may be predicted. These include mutations
S13I and W152C, decreasing antibody binding, N460K, increasing RDB affinity, or Q498R,
positively affecting both properties
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